AVTE Aerovate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVTE

Price (delayed)

$20.29

Market cap

$565.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$542.52M

Highlights
AVTE's debt is down by 38% YoY and by 17% from the previous quarter
The quick ratio has plunged by 58% YoY and by 24% from the previous quarter
The net income has declined by 47% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of AVTE
Market
Shares outstanding
27.86M
Market cap
$565.34M
Enterprise value
$542.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$75.47M
EBITDA
-$75.37M
Free cash flow
-$56.92M
Per share
EPS
-$2.87
Free cash flow per share
-$2.16
Book value per share
$3.96
Revenue per share
$0
TBVPS
$4.84
Balance sheet
Total assets
$127.42M
Total liabilities
$17.96M
Debt
$675,000
Equity
$109.46M
Working capital
$106.6M
Liquidity
Debt to equity
0.01
Current ratio
7.04
Quick ratio
6.94
Net debt/EBITDA
0.3
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.1%
Return on equity
-61.6%
Return on invested capital
-85.7%
Return on capital employed
-68.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVTE stock price

How has the Aerovate Therapeutics stock price performed over time
Intraday
-2.22%
1 week
-6.71%
1 month
-30.32%
1 year
-6.67%
YTD
-10.34%
QTD
-31.38%

Financial performance

How have Aerovate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.41M
Net income
-$75.52M
Gross margin
N/A
Net margin
N/A
AVTE's operating income has dropped by 53% year-on-year and by 8% since the previous quarter
The net income has declined by 47% year-on-year and by 8% since the previous quarter

Growth

What is Aerovate Therapeutics's growth rate over time

Valuation

What is Aerovate Therapeutics stock price valuation
P/E
N/A
P/B
5.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AVTE's EPS is down by 37% year-on-year and by 4.4% since the previous quarter
The price to book (P/B) is 28% more than the last 4 quarters average of 4.0
The company's equity fell by 14% YoY and by 13% QoQ

Efficiency

How efficient is Aerovate Therapeutics business performance
The company's return on invested capital has shrunk by 102% YoY and by 14% QoQ
The return on equity has dropped by 73% year-on-year and by 11% since the previous quarter
The return on assets has dropped by 62% year-on-year and by 9% since the previous quarter

Dividends

What is AVTE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTE.

Financial health

How did Aerovate Therapeutics financials performed over time
The total liabilities has surged by 110% year-on-year and by 19% since the previous quarter
The quick ratio has plunged by 58% YoY and by 24% from the previous quarter
AVTE's debt is 99% less than its equity
AVTE's debt is down by 38% YoY and by 17% from the previous quarter
The company's equity fell by 14% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.